AUS
NZ
UK
CA
USA
IND
Healt
Recce Pharmaceuticals (ASX:RCE) Secures $6.75 Million R&D Tax Incentive Rebate
November 14, 2024 04:39 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals receives a significant $6.75 million R&D tax rebate.,Funds boost Recce’s development of advanced synthetic anti-infectives.,Rebate supports company’s international and domestic R&D initiatives.,Recce Pharmaceuticals (...
Neuren Pharmaceuticals Shares Surge 8.4% on Announcement of AU$50Mn Share Buyback Program
November 14, 2024 12:21 PM AEDT| By Team Kalkine MediaHighlights,Neuren Pharmaceuticals’ shares jumped 8.4% to AU$17.94, marking the highest level since August and making it the top gainer on the ASX 200 index.,The company launched a share buyback program, aiming to repurchase up to 3 million shares wit...
Recce Pharmaceuticals Bolstered by R&D Rebate and Advances in Clinical Trials
November 14, 2024 12:03 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals received over A$6.75 million as an R&D Tax Incentive rebate.,Funds to support global R&D initiatives, including upcoming clinical trials.,Rebate reinforces Australia's commitment to life science innovation.,Recce Phar...
Can BlinkLab’s Tech Revolutionize Autism and ADHD Diagnosis?
November 13, 2024 03:52 PM AEDT| By Team Kalkine MediaHighlights,BlinkLab,collaborates with Monash University on a groundbreaking autism and ADHD study.,The study,utilizes,eye-tracking tech to,identify,unique markers in children with autism and ADHD.,MAGNET project to explore data-driven methods for mor...
Is Paragon Care (ASX:PGC) Enhancing Performance with Smart Financial Strategies?
November 13, 2024 03:21 PM AEDT| By Team Kalkine MediaHighlights,Paragon Care’s stock rose by 11% recently, drawing attention to its financial growth.,ROE highlights Paragon Care’s profitability and reinvestment approach.,Despite a low ROE, Paragon Care’s earnings have grown significantly.,Paragon Care...
IDT Australia’s Takeover Offer from Mynd Falls Through Amid Due Diligence Concerns
November 13, 2024 03:20 PM AEDT| By Team Kalkine MediaHighlights,Proposed,Myndbio,acquisition of IDT Australia canceled after due diligence.,Myndbio,didn’t,finalize,an updated proposal, leaving IDT to end discussions.,IDT grapples with challenges in the cannabis market and aims for future recovery.,IDT...
Will Orthocell's Nerve Repair Product Remplir™ Make Waves in the US Market?
November 12, 2024 06:21 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,eyes the US,$1.6 billion,nerve repair market with,Remplir,™ launch.,New leadership to drive growth as FDA approval expected in early 2025.,Expansion backed by A$35 million in funding to target global markets.,Orthocell (ASX: OCC)...
Pro Medicus (ASX:PME) Stands Out with Strong Earnings Growth and Insider Alignment
November 12, 2024 06:15 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus has seen substantial earnings growth, enhancing shareholder value.,Insiders hold a significant share, aligning their interests with those of other shareholders.,The company’s CEO compensation,remains,moderate, reflecting respon...
Actinogen Secures $9M R&D Rebate to Advance Alzheimer’s Therapy Trial
November 12, 2024 03:07 PM AEDT| By Team Kalkine MediaHighlights,Actinogen,Medical receives a $9 million R&D tax rebate.,Funds support Alzheimer’s therapy trial with 220 participants.,Financial backing ensures operations through mid-2026.,Actinogen Medical Ltd (ASX:ACW) has recently received a substanti...
Recce Pharmaceuticals Advances in Antibiotic Resistance with Trial Approval
November 11, 2024 06:57 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals receives ethics approval for Phase 3 clinical trial in Indonesia.,Company advances towards addressing antibiotic resistance with RECCE 327.,Indonesian clinical trial aims to combat diabetic foot infections.,Recce Phar...
Recce Pharmaceuticals Advances to Phase 3 Trial for Diabetic Foot Infection Treatment in Indonesia
November 11, 2024 04:01 PM AEDT| By Team Kalkine MediaHighlights,Ethics Approval for Phase 3 Trial,: Recce Pharmaceuticals received approval to initiate a large-scale Phase 3 trial in Indonesia for its RECCE® 327 (R327G) topical gel targeting diabetic foot infections.,300-Patient Study Begins in Decembe...
Recce Pharmaceuticals (ASX:RCE) Secures Phase 3 Trial Approval in Indonesia
November 11, 2024 12:56 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals secures ethics approval for Phase 3 trial of R327G in Indonesia.,Trial targets diabetic foot infections with,commercialisation,aimed for 2026.,Bilateral support from Australia and Indonesia enhances trial’s impact in...
Cleanspace Holdings (ASX:CSX) Faces Revenue Slowdown Amid Market Hurdles
November 11, 2024 11:19 AM AEDT| By Team Kalkine MediaHighlights,Cleanspace,shares dip on missed revenue expectations.,Year-to-date revenue growth,remains,flat.,Profitability improves despite minor EBITDA loss.,Cleanspace Holdings (ASX:CSX), a respiratory protection manufacturer, has faced a significant...
Three ASX 200 Stocks Propel Market Gains This Week
November 08, 2024 03:14 PM AEDT| By Team Kalkine MediaHighlights:,Neuren Pharmaceuticals Leads the Week: Neuren Pharmaceuticals (ASX:NEU) saw a 33.8% increase in its share price following positive updates and a significant lump-sum payment.,Sigma Healthcare's Strong Performance: Sigma Healthcare (ASX:SI...
ResMed (ASX: RMD) Shares Evaluated for Future Growth Prospects
November 08, 2024 03:02 PM AEDT| By Team Kalkine MediaHighlights:,ResMed's Strong Financial Performance: A reported 13.6% compound annual growth rate (CAGR) in revenue over the last three years and a 29.1% CAGR in profit.,Debt-Free Capital Structure: The company has a net cash position of $624 million,...
Neuren Pharmaceuticals Shares Surge on Strong Sales
November 08, 2024 01:29 PM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals sees a 13.2% share price increase.,The company reports US sales of its,Daybue,drug surpassing $250 million in the first nine months.,Full-year 2024 income forecasted to range between $216 million and $218 million.,Ne...
Imugene (ASX:IMU) Expands Azer-cel CAR T-cell Lymphoma Trial in Australia
November 08, 2024 12:54 PM AEDT| By Team Kalkine MediaHighlights,Imugene,launches Australian site for,azer,-cel CAR T-cell therapy trial,.,Sydney’s Royal Prince Alfred Hospital to lead DLBCL patient recruitment,.,New phase targets better access and outcomes for lymphoma patients.,Imugene Ltd (ASX:IMU) h...
Mayne Pharma (ASX: MYX) Gains Momentum Amid Strategic Interest Exploration
November 08, 2024 11:35 AM AEDT| By Team Kalkine MediaHighlights,Mayne Pharma shares surge following confirmation of strategic interest.,Jefferies Australia exploring prospective buyers for the company.,Mayne Pharma’s valuation efforts aim to maximize shareholder value.,Mayne Pharma Group Limited (ASX:...
Sigma Healthcare Has Led the Top Gainers as the S&P/ASX 200 Sees a Modest Rise
November 07, 2024 04:44 PM AEDT| By Team Kalkine MediaHighlights:,Sigma Healthcare (ASX) Surges Following Merger Approval,Neuren Pharmaceuticals (ASX) Gains Amid Growing Optimism in Neurological Treatments,Sectors Show Mixed Performance as Market Faces Volatility,The S&P/ASX 200 index saw a modest incre...
Neuren’s ‘Willy Wonka’ Voucher Has Been Revalued at US$50 Million
November 07, 2024 04:34 PM AEDT| By Team Kalkine MediaHighlights:,Neuren Pharmaceuticals (ASX) benefits from a significant windfall through the sale of a US FDA Priority Review Voucher (PRV).,Sigma Healthcare (ASX) and Chemist Warehouse’s merger passes regulatory scrutiny, with no major competition conc...
Advertise your brand on Kalkine Media